Top Line: When and how to dose-esclate radiation for pancreatic cancer is becoming increasingly complex.
The Study: Enter the latest ASTRO guidelines on the subject. Most important: safe dose-escalation. Practically speaking, fractionation should be individualized to the tumor-GI interface at hand and whether dose escalation (read: 65 Gy in 15 fractions versus 75 Gy in 25 fractions) can be achieved while prioritizing luminal constraints with available motion management (ideally end-exhalation breath-hold) and image guidance (ideally daily on-board MRI or CBCT with or without fiducials). Generally, dose-escalated ultra-hypofractionation is reserved for cases with daily online adaptive re-planning enabling safe delivery of 50 Gy over 5 fractions to gross tumor while limiting point dose to adjacent luminal structures to <53 Gy. Next up: elective nodes should be included for non-metastatic cases. For tumors of the head and body this means covering the “triangle” and for tail tumors this means covering splenic regions. Doses to these regions are microscopic—25 Gy in 5, 36 Gy in 15, or 45 Gy in 25—so conceptually it's more about using your dose-fall off to your advantage.
TBL: Five fractions maximize convenience, but 15–25 fractions often maximize the therapeutic window when the tumor-GI interface is unfavorable, and definitive treatment paradigms should include elective nodes in whatever fractionation scheme you land on. | Chuong, Pract Radiat Oncol 2026
The Study: Enter the latest ASTRO guidelines on the subject. Most important: safe dose-escalation. Practically speaking, fractionation should be individualized to the tumor-GI interface at hand and whether dose escalation (read: 65 Gy in 15 fractions versus 75 Gy in 25 fractions) can be achieved while prioritizing luminal constraints with available motion management (ideally end-exhalation breath-hold) and image guidance (ideally daily on-board MRI or CBCT with or without fiducials). Generally, dose-escalated ultra-hypofractionation is reserved for cases with daily online adaptive re-planning enabling safe delivery of 50 Gy over 5 fractions to gross tumor while limiting point dose to adjacent luminal structures to <53 Gy. Next up: elective nodes should be included for non-metastatic cases. For tumors of the head and body this means covering the “triangle” and for tail tumors this means covering splenic regions. Doses to these regions are microscopic—25 Gy in 5, 36 Gy in 15, or 45 Gy in 25—so conceptually it's more about using your dose-fall off to your advantage.
TBL: Five fractions maximize convenience, but 15–25 fractions often maximize the therapeutic window when the tumor-GI interface is unfavorable, and definitive treatment paradigms should include elective nodes in whatever fractionation scheme you land on. | Chuong, Pract Radiat Oncol 2026